PDCD1 and cancer: Despite the immense breakthrough in cancer therapy with the discovery of monoclonal antibodies targeting immune checkpoints, no consistent survival benefit was achieved for patients with aHCC by monotherapy with the anti-programmed cell death 1 (PD-1) mAb nivolumab and pembrolizumab in the first- and second-line setting, respectively [11,12].